Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2009
11/11/2009EP2114987A1 Foxp3 peptide vaccine
11/11/2009EP2114900A1 Thiopyrimidine-based compounds and uses thereof
11/11/2009EP2114442A1 Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
11/11/2009EP2114436A1 Trkb agonists for treating autoimmune disorders
11/11/2009EP2114419A2 Use of arsenic compounds for treatment of pain and inflammation
11/11/2009EP1694331B1 Methods for suppressing an immune response or a treating a proliferating disorder
11/11/2009EP1575964B1 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
11/11/2009EP1557407B1 Novel alpha-ketoamide derivatives and use thereof
11/11/2009EP1519960B1 Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof
11/11/2009EP1482795B1 New immunoeffector compounds
11/11/2009EP1451203B1 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimine nucleosides and uses thereof
11/11/2009EP1450856B1 Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
11/11/2009EP1372634B1 Use of fumaric acid amides
11/11/2009EP1315812B1 Modified polypeptides stabilized in a desired conformation and methods for producing same
11/11/2009EP1191943B1 Anti-allergic peptides
11/11/2009CN101578368A Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
11/11/2009CN101578298A Ligands that bind IL-4 and/or IL-13
11/11/2009CN101578285A Condensed pyridine compound
11/11/2009CN101575383A Preparation method for separating polyose from White Hyacinth Bean
11/11/2009CN101575367A Chinese yam glycosidoprotein and preparation method thereof
11/11/2009CN101575311A Method for preparing epiphysin
11/11/2009CN101574520A Methods of administering anti-TNF alpha antibodies
11/11/2009CN101574509A Agerasia preparation
11/11/2009CN101574474A Traditional Chinese medicine composition for curing purpura
11/11/2009CN101574464A Ageing-resisting and immunity-enhancing capsule prepared by multiple pure traditional Chinese drugs
11/11/2009CN101574460A Nourishing and health preserving liquid medicine
11/11/2009CN101574416A Heat-clearing Ganoderma lucidum polysaccharides health-care capsule
11/11/2009CN101574400A Chinese medicament containing gen-seng and cordyceps
11/11/2009CN101574380A Flavone acetylsalicylate solid dispersion and preparation method thereof
11/11/2009CN101574375A Lactobacillus health-care capsule and preparation method thereof
11/11/2009CN101574364A Preparation capable of improving intelligence, height, athletic ability and immunity and preparation method
11/11/2009CN101574151A Nutritional food with function of strengthening immunity and preparation method thereof
11/11/2009CN101574149A Sugared ginseng powder medicinal granules and preparation method thereof
11/11/2009CN101574148A Ginseng powder medicinal granules
11/11/2009CN100558903C Photochemical internalization for delivery of molecules into the cytosol
11/11/2009CN100558746C Kit for assaying human low-molecular weight CD14 and antibody
11/11/2009CN100558744C Use of a recombinant erythropoietin having high activity and reduced side effects
11/11/2009CN100558718C Piperazinyl and diazapanyl benzamides and benzthioamides
11/11/2009CN100558715C Protein kinase inhibitors
11/11/2009CN100558712C Therapeutic molecules and methods-1
11/11/2009CN100558701C N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists
11/11/2009CN100558410C Nucleic acids, polypeptides, and methods for modulating apoptosis
11/11/2009CN100558405C Pharmaceutical compositions comprising cyclosporin
11/11/2009CN100558401C Adjuvant systems and vaccines
11/11/2009CN100558395C Hybrid peptide modulate immune response
11/11/2009CN100558369C Therapeutical treatments
11/11/2009CN100558368C Method and material for treating immune diseases
11/11/2009CN100558354C Triptolide lactone ring derivatives as immunomodulators and anticancer agents
11/11/2009CN100558349C Ginseng-astragalus capsule formulation and its preparing process
11/11/2009CN100558347C Ginseng-astragalus dispersion tablet formulation, and its preparing process
11/11/2009CN100558256C Method for preparing Chinese magnoliavine fruit functional salad jam
11/10/2009US7615615 Modified interferon beta with reduced immunogenicity
11/10/2009US7615564 Such as N5-[1-(2-chlorobenzyl)tetrahydro-1H-3-pyrrolyl]-5-isoquinolylamine; Rho kinase inhibitors; hypertension, asthma, angina pectoris, cerebrovascular contraction, peripheral circulatory disorder, threatened premature birth, glaucoma, vision disorders, autoimmune diseases, chronic renal failure
11/10/2009US7615562 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents
11/10/2009US7615553 E.g., N,N-dimethyl,((5-(hydroxyaminocarbonyl)pyrimidin-2-yl)(piperazin-1,4-ylene)sulfonamide; bioavailability; oral administration; metabolic stability; side effect reduction; psoriasis; anticarcinogenic -proliferative, -arthritic, -inflammatory agent; gene therapy; genetic transcription potentiation
11/10/2009US7615543 Complexes with C-reactive protein (CRP) molecules; rheumatoid arthritis, juvenile chronic (rheumatoid) arthritis, ankylosing spondylitis, psoriatic arthritis, systemic vasculitis, polymyalgia rheumatica, Reiter's disease, Crohn's disease and familial Mediterranean fever
11/10/2009US7615226 Antigen is mixed with at antigen is mixed with at least one adjuvant and the mixture subsequently is heat-treated
11/10/2009CA2481482C Tropane derivatives as ccr5 modulators
11/10/2009CA2476257C O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
11/10/2009CA2425422C Stable desloratadine salts, process for their synthesis, and pharmaceutical compositions thereof
11/10/2009CA2419887C Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
11/10/2009CA2378792C Aminothiazole derivatives and their use as crf receptor ligands
11/10/2009CA2335903C Novel cyclosporin with improved activity profile
11/10/2009CA2251027C Defective viral vaccine particles obtained in vivo or ex vivo
11/09/2009CA2631071A1 Inhibition of calpain reduces allergic inflammation
11/05/2009WO2009134962A2 Claudin-4 binding peptides, compositions and methods of use
11/05/2009WO2009134738A1 Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
11/05/2009WO2009134429A2 Methods and compositions for modulating immunological tolerance
11/05/2009WO2009134428A2 Methods and compositions for modulating angiogenesis and pericyte composition
11/05/2009WO2009133951A1 Anti-perspiration antigen monoclonal antibody
11/05/2009WO2009133863A1 Immunopotentiating agent comprising ep1 agonist
11/05/2009WO2009133831A1 Phenylpropionic acid derivative and use thereof
11/05/2009WO2009133637A1 Sheet preparation for external use and sheet preparation set for external use
11/05/2009WO2009133294A2 Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules
11/05/2009WO2009133136A1 Compounds
11/05/2009WO2009133127A1 Fused bicyclic compounds and use thereof as pi3k inhibitors
11/05/2009WO2009132941A1 Compositions for treating an arthritic condition
11/05/2009WO2009132821A1 Interleukin (il-21) binding proteins and methods of making and using same
11/05/2009WO2009112245A9 Antibody against the csf-1 r
11/05/2009WO2009108720A3 Antagonists of prostaglandin d2 receptors
11/05/2009WO2009102496A3 Selective agonist of toll-like receptor 3
11/05/2009WO2009046879A3 Use of the combination of npy and nociceptin as a therapeutic agent
11/05/2009WO2009046876A3 Use of a peptide as a therapeutic agent
11/05/2009WO2009043526A3 Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent
11/05/2009WO2009040051A9 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent
11/05/2009WO2009040005A9 Use of the peptide rfmwmr as a therapeutic agent
11/05/2009WO2009033819A3 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
11/05/2009WO2009033797A3 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
11/05/2009WO2009033785A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
11/05/2009WO2009033784A3 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
11/05/2009WO2009033738A3 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
11/05/2009WO2009033712A3 Use of melanotan ii as a therapeutic agent
11/05/2009US20090275656 Medicinal Compositions of Salts, Chelates and/or Free Acids of Alpha Hydroxyl Organic Acids and Related Processes and Methods
11/05/2009US20090275644 Novel adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof
11/05/2009US20090275624 Inhibitors of cdc phosphatases
11/05/2009US20090275611 Compounds Which Modulate The CB2 Receptor
11/05/2009US20090275576 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
11/05/2009US20090275564 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
11/05/2009US20090275554 Aminocarboxylic acid derivative and medicinal use thereof
11/05/2009US20090275553 Dosage regimen of an s1p receptor agonist
1 ... 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 ... 1172